The current financial score of Exagen Inc is 7.59. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 19.94M, representing a year-over-year increase of 15.92%, while its net profit experienced a year-over-year increase of 28.00%.
The current valuation score of Exagen Inc is 8.42. Its current P/E ratio is -9.45, which is -91.77% below the recent high of -0.78 and -41.64% above the recent low of -13.39.
The current earnings forecast score of Exagen Inc is 8.50. The average price target is 9.86, with a high of 12.00 and a low of 9.00.
The current price momentum score of Exagen Inc is 5.52. Currently, the stock price is trading between the resistance level at 8.94 and the support level at 7.36, making it suitable for range-bound swing trading.
The current institutional shareholding score of Exagen Inc is 5.00. The latest institutional shareholding proportion is 58.04%, representing a quarter-over-quarter decrease of 7.71%.
The current risk assessment score of Exagen Inc is 2.52. The company's beta value is 1.99. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.